Form 8-K - Current report:
SEC Accession No. 0001104659-21-031116
Filing Date
2021-03-03
Accepted
2021-03-03 07:41:15
Documents
14
Period of Report
2021-03-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm218544d1_8k.htm   iXBRL 8-K 25474
2 EXHIBIT 99.1 tm218544d1_ex99-1.htm EX-99.1 12195
6 GRAPHIC image_001.jpg GRAPHIC 13641
  Complete submission text file 0001104659-21-031116.txt   234688

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20210303.xsd EX-101.SCH 3190
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20210303_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20210303_pre.xml EX-101.PRE 22713
7 EXTRACTED XBRL INSTANCE DOCUMENT tm218544d1_8k_htm.xml XML 3615
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 21707239
SIC: 2834 Pharmaceutical Preparations